Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. METHODS: Patients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m(2) ever...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219487/
https://ncbi.nlm.nih.gov/pubmed/30361524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0235-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker